Solesence, Inc ((SLSN)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Solesence, Inc.’s latest earnings call painted a transitional quarter marked by near‑term financial pressure but meaningful strategic progress. Management acknowledged revenue decline, a swing to losses, and negative adjusted EBITDA, yet emphasized improving gross margins, a strong order book, new technologies, and concrete operational initiatives, striking a cautiously optimistic tone for the balance of 2026.
Gross Margins Rise Despite Tough Quarter
Solesence reported a 300‑basis‑point gross margin improvement to 26% in Q1 2026, up from roughly 23% a year earlier. The company credited better labor efficiency and elimination of quality‑related waste, suggesting its Transform and Transcend operational efforts are starting to show up in unit economics even as the income statement remains under pressure.
Robust Order Book Underpins Near-Term Visibility
Shipped and open orders totaled $47.0 million, representing a sizable book of business expected to be delivered within the year. This backlog provides some revenue visibility and indicates that end‑market demand remains intact, with operational execution rather than customer appetite the main gating factor for reported sales.
New Technologies Expand Product and Market Reach
The company launched two proprietary technologies, Chromalum and WHSPR, during the quarter, broadening its platform beyond traditional offerings. Management highlighted these SPF‑infused hybrid technologies as a way to enter adjacencies such as hair and scalp care, potentially increasing wallet share with existing partners and opening new category opportunities.
Proven Long-Term Growth and Market Milestones
Over the past six years, Solesence has grown at a compounded annual rate exceeding 50%, underscoring a strong long‑term growth trajectory despite quarterly volatility. The company also reminded investors that it has uplisted to NASDAQ and increased its market capitalization by more than fivefold, framing current challenges within a broader record of value creation.
Operational Overhaul Targets Efficiency Gains
Management detailed several operational initiatives under the Transform and Transcend plan, including an updated shift structure and lean‑manufacturing training. Progress on SIOP implementation, inventory reductions, and a facility consolidation expected to deliver six‑figure annual savings are central to driving sustainable cost improvements and supporting future margin expansion.
Deeper Commercial Ties via Co-Marketing
The company completed four co‑marketing activations with brand partners, including Color Science, BloomAX and Seal, showcasing Solesence‑powered products in the market. These efforts are designed to strengthen strategic relationships, support partners’ sell‑through, and reinforce Solesence’s value proposition at the product level, which could translate into stickier, higher‑quality revenue.
Guidance Reaffirmed: Path Back to Profitability
Solesence reiterated its 2026 guidance, setting a 30% gross profit margin floor for the year and targeting a return to double‑digit EBITDA margins by year‑end. Management plans to fund this recovery through labor‑efficiency gains, SIOP‑driven inventory optimization, and savings from facility consolidation, arguing that current investments should flip from near‑term drag to margin tailwind as the year progresses.
Revenue Hit by Shipment Delays
Q1 2026 revenue declined to $13.0 million from $14.6 million a year earlier, an approximately 11% year‑over‑year drop. The company primarily blamed on‑time, in‑full performance issues and supply alignment problems tied to process changes, which delayed shipments and pushed revenue out of the quarter rather than reflecting weakened demand.
From Modest Profit to Net Loss
Net income swung from a small profit of $0.08 million in Q1 2025 to a loss of $0.8 million this quarter, an adverse change of about $0.88 million. This deterioration illustrates how shipment delays and upfront transformation costs flowed through the P&L, overshadowing the underlying improvement in gross margin.
Adjusted EBITDA Turns Negative
Adjusted EBITDA similarly deteriorated, moving from a positive $609,000 in Q1 2025 to a loss of $107,000 in Q1 2026. While not large in absolute dollar terms, the flip into negative territory highlights the earnings drag from transformation investments that management argues are necessary to unlock future scale and profitability.
OTIF Issues Weigh on Near-Term Performance
On‑time, in‑full performance and supply alignment challenges early in the quarter materially impacted reported results. Management linked these problems to process changes during the implementation of new systems, stressing that they are transitional bottlenecks and a core focus area as the company works to align operations with its evolving business model.
Investments Pressure Profitability in the Short Run
Early‑stage spending under the Transform and Transcend initiative, including updated shift structures, training programs, and operational reorganization, weighed on Q1 profitability. Executives characterized these costs as intentional and front‑loaded, viewing them as enablers of higher efficiency, stronger margins, and more reliable delivery in coming quarters.
Rising Complexity Raises Execution Risk
Management candidly acknowledged that the evolution of its business model has increased operating complexity and execution risk. With new SIOP systems, facility consolidation, and broader product and channel strategies, the challenge now is less about demand generation and more about ensuring the organization can execute consistently at scale.
Forward-Looking Guidance and Execution Priorities
Looking ahead, Solesence is sticking with its Transform and Transcend roadmap, reiterating a 30% gross profit margin floor and a goal of restoring EBITDA margins to at least 10% by year‑end 2026. The company’s confidence rests on a combination of operational efficiencies, cost savings, and conversion of its $47 million order book, but successful execution against rising complexity remains the key swing factor for investors.
Solesence’s earnings call framed Q1 as a reset quarter where transformation costs and operational growing pains overshadowed solid demand and improving margins. For investors, the key takeaway is a business with a strong growth record and sizeable backlog, but one that must now prove it can execute its operational blueprint and deliver the promised return to healthy, sustainable profitability.